Phase I study of karenitecin in the treatment of recurrent malignant gliomas (MG)

被引：0
|
作者：
Lesser, GJ
Grossman, SA
Carson, K
Phupanich, S
Batchelor, T
Peereboom, D
Nabors, LB
Supko, J
Hausheer, F
机构：
[1] Wake Forest Univ, NABTT CNS Consortium, Winston Salem, NC 27109 USA
[2] Johns Hopkins Univ, SOM, Baltimore, MD USA
[3] Emory Univ, Atlanta, GA 30322 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[6] Univ Alabama, Birmingham, AL USA
[7] BioNumerik, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：120S / 120S
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas
    Grossman, Stuart A.
    Carson, Kathryn A.
    Phuphanich, Surasak
    Batchelor, Tracy
    Peereboom, David
    Nabors, L. Burt
    Lesser, Glenn
    Hausheer, Fredrick
    Supko, Jeffrey G.
    NEURO-ONCOLOGY, 2008, 10 (04) : 608 - 616
  • [2] Phase 1 clinical trial and pharmacokinetic study of karenitecin in the treatment of recurrent malignant gliomas: A study of the NABTT CNS Consortium
    Grossman, S
    Supko, J
    Carson, K
    Phuphanich, S
    Batchelor, T
    Peereboom, D
    Nabors, B
    Lesser, G
    Desideri, S
    Hausheer, F
    NEURO-ONCOLOGY, 2005, 7 (03) : 316 - 316
  • [3] Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study
    Casilda Balmaceda
    M. R. Fetell
    Charles Hesdorffer
    Cancer Chemotherapy and Pharmacology, 1997, 40 : 72 - 74
  • [4] Thiotepa and etoposide treatment of recurrent malignant gliomas: Phase I study
    Balmaceda, C
    Fetell, MR
    Hesdorffer, C
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 40 (01) : 72 - 74
  • [5] Phase I/II study of vandetanib for patients with recurrent malignant gliomas.
    Mcnicol, K. A.
    Kreisl, T. N.
    Iwamoto, F. M.
    Sul, J.
    Fine, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas (MG) (NABTC 04-02)
    Chang, S. M.
    Kuhn, J.
    Lamborn, K.
    Cloughesy, T.
    Robins, I.
    Lieberman, F.
    Yung, A.
    Dancey, J.
    Prados, M.
    Wen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A phase I trial of Avonex for patients with recurrent malignant gliomas
    Wen, PY
    Robertson, M
    ONeil, A
    Loeffler, JS
    Black, PM
    Fine, HA
    NEUROLOGY, 1997, 48 (03) : 1003 - 1003
  • [8] PHASE-II STUDY OF SPIROHYDANTOIN MUSTARD FOR THE TREATMENT OF RECURRENT MALIGNANT GLIOMAS
    PRADOS, M
    RODRIGUEZ, L
    SEAGER, M
    SILVER, P
    LEVIN, V
    CANCER TREATMENT REPORTS, 1987, 71 (11): : 1105 - 1106
  • [9] A phase I trial of intratumoral (IT) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MG)
    Forsyth, P. A.
    Roldan, G.
    George, D.
    Wallace, C.
    Morris, D. G.
    Cairncross, G.
    Matthews, M. Vallee
    Markert, J.
    Gillespie, Y.
    Coffey, M.
    Thompson, B.
    Hamilton, M.
    NEURO-ONCOLOGY, 2006, 8 (04) : 442 - 442
  • [10] Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).
    Brickhouse, A.
    Vredenburgh, J. J.
    Gururangan, S.
    Reardon, D. A.
    Desjardins, A.
    Peters, K.
    Herndon, J. E.
    Norfleet, J.
    Marcello, J.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345